ALK-Abelló A/S (CPH:ALK.B)
251.00
-5.00 (-1.95%)
Jun 26, 2026, 4:59 PM CET
ALK-Abelló Employees
ALK-Abelló had 2,613 employees as of December 31, 2025. The number of employees decreased by 140 or -5.09% compared to the previous year.
Employees
2,613
Change (1Y)
-140
Growth (1Y)
-5.09%
Revenue / Employee
2.38M DKK
Profits / Employee
463.94K DKK
Market Cap
55.61B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Novo Nordisk | 67,900 |
| Genmab | 3,088 |
| Coloplast | 17,083 |
| Demant | 26,704 |
| H. Lundbeck | 5,000 |
| Zealand Pharma | 544 |
| Ambu A/S | 5,200 |
| Bavarian Nordic | 1,861 |
ALK-Abelló News
- 12 days ago - EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis - GlobeNewsWire
- 16 days ago - Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap - GlobeNewsWire
- 25 days ago - Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff - GlobeNewsWire
- 4 weeks ago - ALK-Abello initiated with a Buy at Berenberg - TheFly
- 7 weeks ago - ALK-Abelló Quarterly report: Q1 2026 - Filings
- 7 weeks ago - ALK-Abelló Slides: Q1 2026 - Filings
- 7 weeks ago - ALK-Abelló Earnings Call Transcript: Q1 2026 - Transcripts
- 7 weeks ago - ALK-Abelló Quarterly report: Q1 2026 - Filings